Wilbur Kerry, Al-Okka Maha, Jumaat Ebaa, Eissa Nesma, Elbashir Merwa, Al-Yafei Sumaya M Al Saadi
College of Pharmacy, Qatar University, Doha, Qatar.
Pharmacy Department, National Center for Cancer Care and Research, Doha, Qatar.
Patient Prefer Adherence. 2016 Apr 22;10:613-9. doi: 10.2147/PPA.S99718. eCollection 2016.
Cancer treatments are frequently associated with adverse effects, but there may be a cultural reluctance by care providers to be forthcoming with patients regarding these risks for fear of promoting nonadherence. Conversely, research in a number of countries indicates high levels of patient desire for this information. We sought to explore cancer patient experiences, satisfaction, and preferences for medication risk communication in a Middle East care setting.
We developed and administered a ten-item questionnaire (Arabic and English) to a convenience sample of consenting adult patients receiving treatment at the National Center for Cancer Care and Research in Qatar.
One hundred and forty-three patients were interviewed. Most (88%) stated that the level of side effect information they received was sufficient, with physicians (86%) followed by pharmacists (39%) as the preferred sources. The majority (97%) agreed that knowing about possible side effects would help them recognize and manage the reaction, and 92% agreed that it would help them understand how to minimize or prevent the risks. Eighteen percent indicated that this information would make them not want to take treatment. Two-thirds (65%) had previously experienced intolerance to their cancer treatment regimen.
Most patients surveyed expressed preference for the details of possible side effects they may encounter in their treatment. However, one in five considered such information a factor for nonadherence, indicating the need for patient-specific approaches when communicating medication risks.
癌症治疗常常伴有不良反应，但医护人员可能因担心会促使患者不依从治疗，而在文化上不愿向患者坦诚这些风险。相反，一些国家的研究表明患者对这类信息有很高的需求。我们试图在中东地区的医疗环境中探索癌症患者对于药物风险沟通的经历、满意度及偏好。
我们编制并发放了一份包含十个条目的问卷（阿拉伯语和英语），对象是在卡塔尔国家癌症护理与研究中心接受治疗且同意参与的成年患者便利样本。
共访谈了143名患者。大多数（88%）表示他们收到的副作用信息水平足够，首选的信息来源是医生（86%），其次是药剂师（39%）。大多数（97%）同意了解可能的副作用会帮助他们识别和应对不良反应，92%同意这会帮助他们理解如何将风险降至最低或预防风险。18%表示这类信息会使他们不想接受治疗。三分之二（65%）的患者此前曾对其癌症治疗方案不耐受。
大多数接受调查的患者表示希望了解治疗中可能遇到的副作用细节。然而，五分之一的患者认为这类信息是导致不依从治疗的一个因素，这表明在沟通药物风险时需要采用针对患者个体的方法。
Zotero 插件